ap7am logo
Logo Bar bseindia nse-india msn yahoo youtube facebook google thehindu bbc ndtv v6 ABN NTv Tv9 etv namasthetelangaana sakshi andhrajyothy eenadu ap7am bhakti espncricinfo wikipedia twitter

Vitamin D could treat people with multiple sclerosis

Thu, Dec 31, 2015, 01:33 PM
New York, Dec 31: Taking a high dose of vitamin D could be an inexpensive and easy way to treat people with multiple sclerosis (MS), an autoimmune disorder that affects the brain and spinal chord, suggests promising new research.

"These results are exciting, as vitamin D has the potential to be an inexpensive, safe and convenient treatment for people with multiple sclerosis," said study author Peter Calabresi from Johns Hopkins University School of Medicine in the US.

Low levels of vitamin D in the blood are tied to an increased risk of developing MS and are more likely to have greater disability and more disease activity.

The current recommended daily allowance of vitamin D is 600 international units.

For the study, 40 people with relapsing-remitting MS received either 10,400 international units or 800 international units of vitamin D supplements per day for six months.

Patients with severe vitamin D deficiency were not included in the study.

Blood tests at the start of the study and again at three and six months measured the amount of vitamin D in the blood and the response in the immune system's T cells, which play a key role in MS.

While researchers are still determining the optimal level of vitamin D in the blood for people with MS, a suggested range of 40 to 60 nanograms per milliliter (ng/ml) has been proposed as a target.

Participants taking the high dose of vitamin D reached levels within the proposed target, whereas the group taking the low dose did not reach the target.

The people taking the high dose had a reduction in the percentage of inflammatory T cells related to MS severity.

Side effects from the vitamin supplements were minor and were not different between the people taking the high dose and the people taking the low dose, the study found.

The study was published online in the journal of Neurology.
Agency: IANS
X

Feedback Form

Your IP address: 54.204.247.205